Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen

Research output: Contribution to journalJournal articleResearchpeer-review

  1. ESC expert statement on the effects on mood of the natural cycle and progestin-only contraceptives

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. European society of contraception statement on contraception in obese women

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sexual and reproductive health and HIV in border districts affected by migration and poverty in Tanzania

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effekt af behandling med liraglutid på kardiovaskulære biomarkører hos kvinder med PCOS

    Research output: Contribution to journalJournal articleCommunication

  2. Within-day energy deficiency and reproductive function in female endurance athletes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Ingrid J M Duijkers
  • Doris Heger-Mahn
  • Dominique Drouin
  • Sven Skouby
View graph of relations

Objectives Progestogen-only pills (POPs) are safer with respect to cardiovascular risks than contraceptives containing estrogens. Despite the increased contraceptive efficacy of a desogestrel-only pill compared with a traditional POP, POPs are still not widely used due to an unpredictable bleeding pattern. A new POP containing 4 mg drospirenone has been developed with a 24/4 intake regimen which may improve the bleeding pattern. The objectives of this study were to investigate ovulation inhibition with the new drospirenone-only pill in comparison with the desogestrel-only pill and, in addition, to assess the effects on cervical mucus permeability and bleeding. Methods Sixty-four healthy volunteers with proven ovulatory cycles were randomised and treated with either the drospirenone-only or the desogestrel-only pill during two 28-day cycles. Follicular diameter, endometrial thickness, and serum estradiol (E2) and progesterone concentrations were measured and Hoogland scores were determined. Additionally, cervical mucus scores, bleeding and return of ovulation were assessed. Results Both treatments effectively inhibited ovulation. Follicular diameter, E2 levels and Hoogland scores were equal, demonstrating efficient ovarian suppression. One subject in each group had a Hoogland score of 6, but the criteria for normal luteal activity were not fulfilled. In both groups, ovulation did not occur before day 9 of the post-treatment cycle. Cervical mucus permeability was suppressed in both groups. The median number of bleeding and spotting days was lower in the drospirenone group. Conclusions The new drospirenone-only pill inhibited ovulation as effectively as the desogestrel-only pill despite the 4-day hormone-free interval. Chinese Abstract ,。,,,。4,24/4。,,。 64,28。、、,Hoogland。,、。 。、Hoogland,。Hoogland6,。9,。。,。 4,。 ;;;;;.

Original languageEnglish
JournalThe European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
Volume20
Issue number6
Pages (from-to)419-27
Number of pages9
ISSN1362-5187
DOIs
Publication statusPublished - Dec 2015

ID: 45718724